Introduction
============

Approximately one-third of all ischemic strokes (IS) are characterized as cryptogenic strokes (CS), due to the lack of a possible cause for the event or incomplete diagnostic work-up \[[@b1-jos-2019-01067]-[@b3-jos-2019-01067]\]. Atrial fibrillation (AF), either paroxysmal or chronic, represents a major risk factor for stroke and systemic embolism, and is associated with a 5-fold increase in IS risk \[[@b4-jos-2019-01067],[@b5-jos-2019-01067]\]. Although paroxysmal AF appears to be implicated in at least 30% of patients with CS and in approximately 25% of patients with unselected IS \[[@b6-jos-2019-01067],[@b7-jos-2019-01067]\], current guidelines on secondary stroke prevention do not provide firm directions on AF screening after IS.

The American Heart Association/American Stroke Association (AHA/ASA) recommendations on secondary stroke prevention suggest that prolonged rhythm monitoring for approximately 30 days is reasonable for AF screening within 6 months after CS (Class IIa; Level of Evidence C) \[[@b8-jos-2019-01067]\], while the recent AHA/ASA guidelines on the early management of IS patients indicate that the clinical benefit of prolonged cardiac monitoring to detect AF remains uncertain (Class of Recommendation: IIb, Level of Evidence: B) \[[@b9-jos-2019-01067]\]. However, clinical trials \[[@b6-jos-2019-01067],[@b10-jos-2019-01067]\] suggest that implantable cardiac monitors (ICMs) substantially increase AF detection in IS patients, due to prolonged monitoring duration.

In the present systematic review and meta-analysis, we sought to investigate the association of ICM duration with the level of AF detection in IS patients. We also assessed whether IS subtype, patient characteristics, and elapsed time between IS onset and CM implantation may affect the probability of AF detection.

Methods
=======

Search strategy and selection criteria
--------------------------------------

This study was conducted according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@b11-jos-2019-01067]\]. We searched for studies reporting AF detection rates by ICM in patients with history of IS or transient ischemic attack (TIA). A literature search in MEDLINE, SCOPUS, and the Cochrane Central Register of Controlled Trials (CENTRAL) was performed, using the following terms in combination: "cardiac monitoring," "implantable loop recorder," "insertable loop recorder," "implantable cardiac monitor," "cryptogenic stroke," "embolic stroke of undetermined source," "ischemic stroke," "cerebral ischemia," "atrial fibrillation," and "atrial flutter." The complete algorithm used in the MEDLINE database search is available in the online [Supplementary Methods](#SD1-jos-2019-01067){ref-type="supplementary-material"}. Eligible studies were also sourced from a manual search of key journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses. No language or other search restrictions were applied. The last literature search was performed on July 10, 2018.

We included all studies (randomized clinical trials \[RCTs\], prospective/retrospective cohort studies, case-control studies) reporting detection rates of AF by ICM in patients with history of IS or TIA. We excluded from further evaluation all case reports, case series, studies reporting cardiac monitoring with devices other than ICM, and studies not providing AF detection rate or monitoring duration with ICM. We also excluded studies reporting overlapping population data, and included only the study with the highest number of patients and/or more extended follow-up time. However, we retained publications providing data for distinct IS groups, including CS and embolic stroke of undetermined source (ESUS), despite the possibility of overlapping group data (ESUS overlapping with CS, and CS/ESUS overlapping with unselected IS/TIA). Reference lists of all articles that met the inclusion criteria, and of relevant review articles, were examined to identify studies that may have been missed by the initial database search. All retrieved studies were scanned independently by two reviewers (G.T. and A.H.K.). In case of disagreement regarding the literature search results between the two coauthors, the remaining coauthors were consulted, and disagreement was ultimately resolved with consensus. We used the Newcastle-Ottawa Scale to assess the quality of included studies that were published at the time of the literature search, and to identify potential sources of bias amongst eligible studies \[[@b12-jos-2019-01067]\]. Quality control and bias identification were performed independently by the same authors who performed the literature search (G.T. and A.H.K.), and all potential disagreements were resolved after discussion and mutual consensus.

The minimum required AF duration, for diagnosing AF with ICM, was documented separately for each study protocol. We calculated the ICM AF detection rates for different ICM durations by dividing the number of events (patients with detected AF) by the total number of patients receiving ICM. After the overall analysis we performed meta-regression analyses for all study and patient characteristics that were available in 10 or more of the included studies \[[@b13-jos-2019-01067]\]. We also conducted pre-defined subgroup analyses according to the study type (prospective or retrospective cohort), study population (CS, ESUS, unselected IS/TIA), the specific time threshold used for AF diagnosis (30 seconds, 2 minutes, 6 minutes), the monitoring duration (\<6, ≥6 and ≤12, \>12 and ≤24, \>24 months), the ICM device used, and the elapsed time between IS/TIA onset and implantation of CM (≤1 and \>1 month), provided that at least two studies were included in each subgroup. Finally, for all the aforementioned meta-regression and subgroup analyses, we performed additional sensitivity analyses after excluding studies that were presented in conferences and had only abstracts publicly available at the time of the literature search. Data extraction was performed by two independent authors (A.H.K. and L.P.), and in cases of disagreement, a senior author (G.T.) was consulted.

For all proportion analyses we used the variance-stabilizing double arcsine transformation \[[@b14-jos-2019-01067]\]. Pooled estimates in both the overall and subgroup analyses were calculated using the Hartung-Knapp-Sidik-Jonkman method \[[@b15-jos-2019-01067]\]. Meta-regression analyses were performed under the random-effects model (method of moments). Variables with a threshold of *P*\<0.1 in the initial univariate meta-regression analyses were used as covariates for multivariate meta-regression models. Due to the established relationship of age with AF incidence \[[@b16-jos-2019-01067]\], mean age was included as an *a priori* potential confounder in all multivariate models. The equivalent z test was performed for each pooled estimate and *P*\<0.05 was considered statistically significant. We assessed heterogeneity between studies with the Cochran Q and I^2^ statistics \[[@b17-jos-2019-01067]\]. For all subgroup analyses we used a standard test for heterogeneity across subgroup results, to investigate for potential differences between subgroups, as previously described \[[@b18-jos-2019-01067]\]. Small-study effect (i.e., publication bias) across individual studies was evaluated graphically using both funnel plot inspection and the Egger's linear regression test, at a significance level of 0.1 \[[@b19-jos-2019-01067]\].

All statistical analyses were performed using Stata Statistical Software Release version 13 for Windows (StataCorp LP, College Station, TX, USA) and OpenMeta-Analyst software \[[@b20-jos-2019-01067]\].

Since the present work is a systematic review and metaanalysis of previously published studies, IRB approval was waived.

Results
=======

The PRISMA flowchart summarizing the literature search process is shown in [Supplementary Figure 1](#SD7-jos-2019-01067){ref-type="supplementary-material"}. MEDLINE and SCOPUS literature searches retrieved 375 and 417 results respectively, while comprehensive searches of key journals and conference proceedings identified 20 additional studies. Of all potentially eligible studies, 18 study protocols were excluded ([Supplementary Table 1](#SD2-jos-2019-01067){ref-type="supplementary-material"}) due to overlapping data (n=4), the use of monitoring devices other than ICM (n=11), or unavailable information on ICM duration (n=3). Our literature search highlighted 28 studies for inclusion, comprising 4,531 patients (mean age 65 years, 52% male) \[[@b6-jos-2019-01067],[@b21-jos-2019-01067]-[@b48-jos-2019-01067]\]. Protocols and patient characteristics of included studies are briefly summarized in [Table 1](#t1-jos-2019-01067){ref-type="table"} and [Supplementary Table 2](#SD3-jos-2019-01067){ref-type="supplementary-material"}, respectively. Most studies were conducted in the USA (n=9) and Germany (n=8). The most common subgroup studied was cryptogenic IS/TIA (n=17), followed by ESUS (n=9). The mean/median elapsed time from IS/TIA onset to cardiac monitoring implantation ranged from 3 to 174 days, while the mean/median ICM duration ranged from 180 to 1,080 days ([Table 1](#t1-jos-2019-01067){ref-type="table"}). Included studies were generally found to have a low risk of bias ([Supplementary Table 3](#SD4-jos-2019-01067){ref-type="supplementary-material"}), except in cases not clearly stating consecutive enrollment of patients \[[@b23-jos-2019-01067],[@b26-jos-2019-01067],[@b27-jos-2019-01067],[@b39-jos-2019-01067],[@b44-jos-2019-01067]-[@b47-jos-2019-01067]\], exclusion of AF with electrocardiogram or short-term non-invasive Holter monitoring prior to ICM impantation \[[@b21-jos-2019-01067],[@b33-jos-2019-01067]\], or no adjudication of ICM recordings by experienced cardiologists \[[@b26-jos-2019-01067]-[@b29-jos-2019-01067],[@b33-jos-2019-01067],[@b41-jos-2019-01067],[@b46-jos-2019-01067],[@b47-jos-2019-01067]\].

In the overall analysis of all included studies, the cumulative AF detection rate in patients with ICM was 26% (95% confidence interval \[CI\], 22% to 30%), with significant heterogeneity among studies (I^2^=83%, *P* for Cochran Q \<0.001) ([Supplementary Figure 2](#SD8-jos-2019-01067){ref-type="supplementary-material"}). No evidence for publication bias was identified by funnel plot inspection ([Supplementary Figure 3](#SD9-jos-2019-01067){ref-type="supplementary-material"}) or by the Egger's statistical test (*P*=0.525). In univariate meta-regression analyses of all included studies ([Table 2](#t2-jos-2019-01067){ref-type="table"}) the proportion of AF detection by ICM was positively associated with the duration of monitoring (coefficient=0.009; 95% CI, 0.005 to 0.013; *P*\<0.001) ([Figure 1A](#f1-jos-2019-01067){ref-type="fig"}) and mean patient age (*P*=0.018) ([Supplementary Figure 4A](#SD10-jos-2019-01067){ref-type="supplementary-material"}). No associations were detected with other patient characteristics ([Supplementary Figures 5A](#SD11-jos-2019-01067){ref-type="supplementary-material"} and [9A](#SD15-jos-2019-01067){ref-type="supplementary-material"}), including sex (*P*=0.100) ([Supplementary Figure 5A](#SD11-jos-2019-01067){ref-type="supplementary-material"}), hypertension (*P*=0.215) ([Supplementary Figure 6A](#SD12-jos-2019-01067){ref-type="supplementary-material"}), diabetes mellitus (*P*=0.140) ([Supplementary Figure 7A](#SD13-jos-2019-01067){ref-type="supplementary-material"}), mean patient CHA~2~DS~2~-VASc score (*P*=0.232) ([Supplementary Figure 8A](#SD14-jos-2019-01067){ref-type="supplementary-material"}), or elapsed time from IS/TIA onset to cardiac monitor implantation (*P*=0.363) ([Supplementary Figure 9A](#SD15-jos-2019-01067){ref-type="supplementary-material"}). In multivariate analyses, both monitoring duration (coefficient=0.015; 95% CI, 0.005 to 0.024; *P*=0.003) and mean patient age (coefficient=0.009; 95% CI, 0.003 to 0.015; *P*=0.004) were independently associated with the proportion of AF detection ([Table 2](#t2-jos-2019-01067){ref-type="table"}).

In the sensitivity univariate meta-regression analyses of published studies ([Supplementary Table 4](#SD5-jos-2019-01067){ref-type="supplementary-material"}) duration of ICM (coefficient=0.007; 95% CI, 0.001 to 0.014; *P*=0.049) ([Figure 1](#f1-jos-2019-01067){ref-type="fig"}B), history of hypertension (coefficient=0.005; 95% CI, 0.001 to 0.010; *P*=0.029) ([Supplementary Figure 6B](#SD12-jos-2019-01067){ref-type="supplementary-material"}), and diabetes mellitus (coefficient=0.013; 95% CI, 0.001 to 0.024; *P*=0.033) ([Supplementary Figure 7B](#SD13-jos-2019-01067){ref-type="supplementary-material"}) were positively associated with higher rates of AF detection, while no association was detected with other patient characteristics ([Supplementary Figures 4B](#SD10-jos-2019-01067){ref-type="supplementary-material"}, [5B](#SD11-jos-2019-01067){ref-type="supplementary-material"}, [8B](#SD14-jos-2019-01067){ref-type="supplementary-material"}, and [9B](#SD15-jos-2019-01067){ref-type="supplementary-material"}). However, in multivariate analyses only monitoring duration (coefficient=0.009; 95% CI, 0.003 to 0.015; *P*=0.006) and mean patient age (coefficient=0.037; 95% CI, 0.013 to 0.062; *P*=0.007) were independently associated with the proportion of AF detection ([Supplementary Table 4](#SD5-jos-2019-01067){ref-type="supplementary-material"}).

In subgroup analyses of all included studies ([Table 3](#t3-jos-2019-01067){ref-type="table"}), there were significant differences (*P* for subgroup differences \<0.001) in the rates of AF detection in subgroups stratified by ICM duration (\<6 months: 5% \[95% CI, 3% to 6%\]; ≥6 and ≤12 months: 21% \[95% CI, 16% to 25%\]; \>12 and ≤24 months: 26% \[95% CI, 22% to 31%\]; and \>24 months: 34% \[95% CI, 29% to 39%\]) ([Supplementary Figure 10](#SD16-jos-2019-01067){ref-type="supplementary-material"}). No differences were found in the subgroup analyses of all included studies stratified by study type (*P*=0.178) ([Supplementary Figure 11](#SD17-jos-2019-01067){ref-type="supplementary-material"}), IS/TIA subgroup (*P*=0.093) ([Supplementary Figure 12](#SD18-jos-2019-01067){ref-type="supplementary-material"}), the time threshold used for AF definition (*P*=0.234) ([Supplementary Figure 13](#SD19-jos-2019-01067){ref-type="supplementary-material"}), the elapsed time from IS/TIA onset to cardiac monitor implantation (P \>0.999) ([Supplementary Figure 14](#SD20-jos-2019-01067){ref-type="supplementary-material"}) or the device used (*P*=0.174) ([Supplementary Figure 15](#SD21-jos-2019-01067){ref-type="supplementary-material"}). Similarly, in the subgroup analysis of published studies ([Supplementary Table 5](#SD6-jos-2019-01067){ref-type="supplementary-material"}) there were significant differences (*P* for subgroup differences \<0.001) in AF detection rates in subgroups stratified by ICM duration (\<6 months: 5% \[95% CI, 3% to 6%\]; ≥6 and ≤12 months: 22% \[95% CI, 16% to 28%\]; and \>12 and ≤24 months: 22% \[95% CI, 14% to 29%\]) ([Supplementary Figure 16](#SD22-jos-2019-01067){ref-type="supplementary-material"}). There were no differences in subgroup analyses of published studies stratified by IS/TIA subtype (*P*=0.429) ([Supplementary Figure 17](#SD23-jos-2019-01067){ref-type="supplementary-material"}), the time threshold used for AF definition (*P*=0.149) ([Supplementary Figure 18](#SD24-jos-2019-01067){ref-type="supplementary-material"}), the elapsed time from IS/TIA onset to cardiac monitor implantation (*P*=0.864) ([Supplementary Figure 19](#SD25-jos-2019-01067){ref-type="supplementary-material"}), or the device used (*P*=0.174) ([Supplementary Figure 20](#SD26-jos-2019-01067){ref-type="supplementary-material"}). In the aforementioned subgroup analyses, considerable heterogeneity was found within all subgroups (I^2^\>70%), except for the subgroup of studies reporting the 6 min interval as a threshold for AF detection (I^2^=8%) and the subgroup of studies reporting more than 24 months of ICM duration (I^2^=24%).

Finally, in a post hoc analysis of available studies, we found that among IS/TIA patients with AF detected during ICM, a total of 87% (95% CI, 78% to 96%) experienced asymptomatic AF episodes ([Supplementary Figure 21](#SD27-jos-2019-01067){ref-type="supplementary-material"}), with no evidence of heterogeneity between studies (I^2^=29%, *P* for Cochran Q=0.21).

Discussion
==========

Our meta-analysis showed that AF detection in patients with history of IS/TIA is positively associated only with the duration of ICM and patient age. We failed to find any other independent association between AF detection rates and IS/TIA subtype, device type, other patient characteristics, or elapsed time between IS/TIA onset and cardiac monitor implantation. Approximately nine out of 10 patients, with positive ICM for AF, experienced asymptomatic AF episodes during the monitoring period.

Our findings agree with a previously published systematic review and meta-analysis reporting improved AF detection with ICM, compared to wearable devices, in CS patients (23.3% \[95% CI, 13.83% to 32.29%\] vs. 13.6% \[95% CI, 7.91% to 19.32%\]; *P* for subgroup differences \<0.05) \[[@b49-jos-2019-01067]\]. However, compared to the previous meta-analysis, we included a significantly higher number of studies and patients (seven studies with 774 patients vs. 28 studies with 4,531 patients). Moreover, we assessed the potential modifying effect of stroke subtype, baseline characteristics, and time interval between ischemic event and implantation.

AF detection rates in patients with IS/TIA were unrelated to any patient characteristics, except for mean patient age. Although increased age, increased stroke severity, left atrial enlargement, hypertension, congestive heart failure, and valvular heart disease have been associated with increased incidence of AF detection in IS patients \[[@b50-jos-2019-01067]\], proposed prediction scores including these parameters have limited diagnostic yield, especially at their middle grades \[[@b51-jos-2019-01067]\]. Our meta-analysis also provides no further support to the theoretical concern regarding increased AF detection during the immediate post-IS period, due to stroke-induced sympathetic activation \[[@b52-jos-2019-01067]\]. Finally, the results of subgroup analysis, regarding the time threshold used for AF definition, do not confirm the association of improved ICM performance with increased duration of AF episodes \[[@b53-jos-2019-01067]\].

Another intriguing finding was that we observed no differences in AF detection rates using ICM, between CS and ESUS patients. This observation challenges the notion that paroxysmal AF is the main underlying etiopathogenic mechanism of cerebral ischemia in ESUS patients \[[@b54-jos-2019-01067]\] and is in line with the recently reported New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) trial, where the detection rate of symptomatic AF during an approximate 1-year follow-up period was only 3% \[[@b55-jos-2019-01067]\].

Several limitations of the present study need to be acknowledged. Firstly, it should be noted that baseline characteristics of individual patients ([Supplementary Table 2](#SD3-jos-2019-01067){ref-type="supplementary-material"}) and study protocol parameters ([Table 1](#t1-jos-2019-01067){ref-type="table"}) were unavailable in a significant proportion of included studies, and particularly in abstracts from conference proceedings. Moreover, the presence of ecological bias cannot be excluded; thus, the associations of aggregate patient characteristics may not hold true also for individual patient characteristics. Secondly, since this is a studylevel meta-analysis, we could not assess the influence of other parameters on AF detection rates that were not originally provided by included studies, e.g., the recently published hypertension, age, valvular heart disease, peripheral vascular disease, obesity, congestive heart failure, and coronary artery disease (HAVOC) score \[[@b49-jos-2019-01067]\]. Thirdly, although meta-regression analyses did not provide evidence for any association bet=ween reported study characteristics (except for hypertension history) and AF detection rate, there is a possibility that heterogeneity in AF incidence could at least partially reflect inherent differences in the patient populations of included studies. Additionally, it should be highlighted that the lack of significant associations could be attributed to the low statistical power, especially for analyses including a low number of studies. Finally, it should be noted that in the present meta-analysis, we did not assess the number of AF episodes, false positive AF episodes, cumulative AF episode duration, or the impact of AF detection in patient management and long-term outcomes \[[@b56-jos-2019-01067]\].

Our findings challenge current AHA/ASA guidelines \[[@b8-jos-2019-01067],[@b9-jos-2019-01067]\], while further highlighting the indispensable role of prolonged rhythm monitoring, using ICM in the identification of a substantial portion of IS/TIA patients with occult AF. According to current recommendations, secondary CS prevention strategies are mainly based on antiplatelet therapy \[[@b6-jos-2019-01067]\], which is known to provide inadequate protection for patients with AF. In these patients, the systemic administration of anticoagulant therapy could contribute to an 8.4% annual absolute risk reduction of stroke recurrence, compared with antiplatelet therapy \[[@b57-jos-2019-01067]\]. Also taking into account the negative results of the recent NAVIGATE ESUS trial, showing that rivaroxaban compared to aspirin increases major bleeding without reducing ischemic events in ESUS patients \[[@b54-jos-2019-01067]\], ICM emerges as an extremely useful diagnostic tool to identify those patients with occult AF within the heterogeneous group of ESUS or CS patients \[[@b58-jos-2019-01067]\]. Therefore, prolonged monitoring could have a substantial impact on the secondary prevention of CS patients with underlying AF, leading to prompt anticoagulant initiation and lower stroke recurrence \[[@b59-jos-2019-01067]\]. The Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) study, guided by implantable loop recorder \[[@b60-jos-2019-01067]\] and the AF detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (LOOP) study \[[@b61-jos-2019-01067]\] are two ongoing, multicenter, open-label RCTs, that aim to evaluate health benefits, including reduction of recurrent ischemic events and cost-effectiveness of ICM in secondary stroke prevention. Results from these studies will further characterize the target population for ICM, the optimal threshold for AF definition and whether ICM monitoring results in lower stroke recurrence through anticoagulant initiation.

In conclusion, the results of the present meta-analysis support extended-duration ICM monitoring as a reasonable option for patients with IS or TIA, and initial negative screening for AF detection \[[@b62-jos-2019-01067]\], that may substantially enhance detection of predominantly subclinical AF episodes.
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###### 

Characteristics of included studies

  Study                                                                                                         Country       No. of patients   Population   Device                  Monitoring time (day)   Implantation after event (day)   Insertion to AF detection (day)   AF definition
  ------------------------------------------------------------------------------------------------------------- ------------- ----------------- ------------ ----------------------- ----------------------- -------------------------------- --------------------------------- ---------------
  Asaithambi et al. (2017) \[[@b21-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^           USA           114               CS           NR                      415 (268--557)          NA                               53 (5--132)                       NA
  Carrazco et al. (2018) \[[@b22-jos-2019-01067]\]                                                              USA           100               CS           Reveal XT/Reveal LINQ   240--540                4.2±2.6                          34                                \>2 min
  Ching et al. (2018) \[[@b23-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^                USA           177               ESUS         Reveal LINQ             478±179                 NA                               NA                                NA
  Cotter et al. (2013) \[[@b24-jos-2019-01067]\]                                                                UK            51                CS           Reveal XT               229±116                 174±134                          48                                \>2 min
  CRYSTAL-AF (2014) \[[@b6-jos-2019-01067]\]                                                                    Multicenter   221               CS           Reveal XT               1,080                   38.1±27.6                        41 (14--84)                       \>30 sec
  CRYSTAL-AF (2017) \[[@b25-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^                  Multicenter   122               ESUS         Reveal XT               NA                      NA                               NA                                ≥2 min
  de Lera et al. (2016) \[[@b26-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^              Spain         163               ESUS         NR                      616±340                 NA                               NA                                \>2 min
  Dion et al. (2010) \[[@b27-jos-2019-01067]\]                                                                  France        24                CS           Reveal Plus ILR 9526    435                     90±30.3                          NA                                \>30 sec
  Etgen et al. (2013) \[[@b28-jos-2019-01067]\]                                                                 Germany       22                CS           Reveal XT               360                     8.5 (6.5--10.5)                  152.8 (61.6--244.1)               \>6 min
  Israel et al. (2017) \[[@b29-jos-2019-01067]\]                                                                Germany       123               ESUS         Reveal XT               381±165                 20                               108                               \>2 min
  Jorfida et al. (2016) \[[@b30-jos-2019-01067]\]                                                               Italy         54                CS           Reveal XT               435 (261--675)          108±60                           162 (30--540)                     \>5 min
  Kamel et al. (2018) \[[@b31-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^                USA           886               Unselected   NR                      720                     NA                               NA                                NA
  Katz et al. (2017) \[[@b32-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^                 USA           45                Unselected   Reveal LINQ             264                     10                               162.7                             NA
  Kotlarz-Böttcher et al. (2018) \[[@b33-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^     Germany       100               ESUS         Reveal LINQ             362                     NA                               NA                                NA
  Makimoto et al. (2017) \[[@b34-jos-2019-01067]\]                                                              Germany       146               ESUS         NR                      387 (283--552)          NA                               NA                                \>30 sec
  Navarro Pérez et al. (2018) \[[@b35-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^        Spain         37                CS           NR                      337.95                  226.6                            82.5                              NA
  Noone et al. (2016) \[[@b36-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^                Ireland       31                ESUS         NR                      540                     NA                               90                                \>30 sec
  Pallesen et al. (2017) \[[@b37-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^             Germany       75                ESUS         Reveal LINQ             NA                      NA                               57                                NA
  Poli et al. (2016) \[[@b38-jos-2019-01067]\]                                                                  Germany       74                CS           Reveal XT/Reveal LINQ   311±251                 27±24                            105±135                           \>2 min
  REVEAL-AF (2018) \[[@b39-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^                   Multicenter   79                Unselected   Reveal XT/Reveal LINQ   540--900                \-                               \-                                \>6 min
  Ritter et al. (2013) \[[@b40-jos-2019-01067]\]                                                                Germany       60                CS           Reveal XT               382 (89--670)           13 (10--67)                      64                                \>30 sec
  Rodríguez-Campello et al. (2015) \[[@b41-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^   Spain         28                ESUS         NR                      180 (60--360)           5--7                             12 (10--21)                       NA
  Rojo-Martinez et al. (2013) \[[@b42-jos-2019-01067]\]                                                         Spain         101               CS           Reveal XT               281±212                 \<30                             102                               \>2 min
  Sethi et al. (2017) \[[@b43-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^                USA           197               CS           NR                      454 (50--951)           3                                NA                                NA
  SPIDER Registry (2015) \[[@b44-jos-2019-01067]\]^[\*](#tfn1-jos-2019-01067){ref-type="table-fn"}^             USA           64                CS           Reveal XT/Reveal LINQ   223                     NA                               35                                \>10 sec
  SURPRISE (2014) \[[@b45-jos-2019-01067]\]                                                                     Denmark       85                CS           Reveal XT               569±310                 107±117                          109±48                            \>2 min
  TRACK-AF (2018) \[[@b46-jos-2019-01067]\]                                                                     Germany       105               CS           Reveal XT               217 (72.5--338)         0--28                            NA                                \>30 sec
  Ziegler et al. (2015) \[[@b47-jos-2019-01067]\], (2017) \[[@b48-jos-2019-01067]\]                             USA           1,247             CS           Reveal LINQ             579±222                 NA                               112 (35--293)                     \>2 min

Values are presented as median (interquartile range), range, or mean±standard deviation.

AF, atrial fibrillation; CS, cryptogenic stroke; NA, not available; ESUS, embolic stroke of undetermined source; CRYSTAL-AF, Cryptogenic Stroke and underlying Atrial Fibrillation; REVEAL AF, Incidence of AF in High Risk Patients; SPIDER Registry, Stroke Prevention through the Improved Detection of AF registry; SURPRISE, Stroke Prior to Diagnosis of Atrial Fibrillation Using Long-term Observation with Implantable Cardiac Monitoring Apparatus Reveal; TRACK-AF, Followup of Kryptogenic Stroke Patients With Implantable vs. Non-invasive Devices to Detect Atrial Fibrillation.
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###### 

Univariate and multivariate meta-regression analyses of the association of patient and study characteristics with the percentage of patients detected with atrial fibrillation after implantable loop recorder insertion

  Variable                                          Univariate meta-regression analysis   Multivariate meta-regression analysis                                         
  ------------------------------------------------- ------------------------------------- --------------------------------------- --------- ---- ---------------------- -------
  Age                                               30                                    0.013 (0.002 to 0.024)                  0.018     30   0.009 (0.003--0.015)   0.004
  Male gender                                       29                                    --0.008 (--0.018 to 0.002)              0.100     \-   \-                     \-
  Hypertension                                      19                                    0.003 (--0.002 to 0.008)                0.215     \-   \-                     \-
  Diabetes mellitus                                 17                                    0.009 (--0.003 to 0.021)                0.140     \-   \-                     \-
  CHA2DS2-VASc score                                13                                    0.079 (--0.058 to 0.216)                0.232     \-   \-                     \-
  Duration of monitoring                            45                                    0.009 (0.005 to 0.013)                  \<0.001   30   0.015 (0.005--0.024)   0.003
  Time from event to cardiac monitor implantation   19                                    0.001 (--0.001 to 0.002)                0.363     \-   \-                     \-

CI, confidence interval.

###### 

Subgroup analyses of the association of baseline characteristics with the percentage of patients detected with atrial fibrillation after implantable loop recorder insertion

  Subgroup                                                      Number   AF detection (95% CI) (%)   Within subgroup heterogeneity, I^2^ (%)   Subgroups difference, *P*
  ------------------------------------------------------------- -------- --------------------------- ----------------------------------------- ---------------------------
  Monitoring duration (mo)                                                                                                                     
   \<6                                                          2        5 (3--6)                    0                                         \<0.001
   ≥6 and ≤12                                                   19       21 (16--25)                 81                                        
   \>12 and ≤24                                                 20       26 (22--31)                 82                                        
   \>24                                                         4        34 (29--39)                 24                                        
  IS/TIA subtype                                                                                                                               
   CS                                                           24       21 (17--25)                 95                                        0.093
   ESUS                                                         14       29 (23--35)                 84                                        
   Unselected                                                   7        23 (17--30)                 84                                        
  AF time threshold                                                                                                                            
   \>30 sec                                                     9        17 (9--26)                  89                                        0.234
   \>2 min                                                      18       25 (20--30)                 97                                        
   \>6 min                                                      6        25 (20--30)                 8                                         
  Time from IS/TIA onset to cardiac monitor implantation (mo)                                                                                  
   ≤1                                                           11       23 (16--30)                 86                                        \>0.999
   \>1                                                          10       23 (15--31)                 90                                        
  Study type                                                                                                                                   
   Prospective                                                  43       24 (20--27)                 95                                        0.178
   Retrospective                                                2        30 (22--38)                 0                                         
  ICM device                                                                                                                                   
   Reveal XT                                                    10       27 (21--33)                 75                                        0.174
   Reveal LINQ                                                  5        19 (12--27)                 61                                        
   Reveal XT/LINQ                                               4        28 (21--36)                 87                                        

AF, atrial fibrillation; CI, confidence interval; IS, ischemic stroke; TIA, transient ischemic attack; CS, cryptogenic stroke; ESUS, embolic stroke of undetermined source; ICM, implantable cardiac monitor.
